This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    ALD403-CLIN-011
Previous Study | Return to List | Next Study

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Alder Biopharmaceuticals, Inc.
Information provided by (Responsible Party):
Alder Biopharmaceuticals, Inc. Identifier:
First received: November 23, 2016
Last updated: July 11, 2017
Last verified: July 2017
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

Condition Intervention Phase
Migraine Disorders Biological: ALD403 (Eptinezumab) Biological: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine

Resource links provided by NLM:

Further study details as provided by Alder Biopharmaceuticals, Inc.:

Primary Outcome Measures:
  • Change in frequency of migraine days [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Responder rate [ Time Frame: 4 weeks ]
  • Responder rate [ Time Frame: 12 weeks ]
  • Laboratory variables, ECG and adverse events [ Time Frame: 36 weeks ]

Estimated Enrollment: 1050
Study Start Date: November 2016
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALD403 (Eptinezumab) Dose Level 1
ALD403 (Eptinezumab) Dose Level 1 (IV)
Biological: ALD403 (Eptinezumab)
Experimental: ALD403 (Eptinezumab) Dose Level 2
ALD403 (Eptinezumab) Dose Level 2 (IV)
Biological: ALD403 (Eptinezumab)
Placebo Comparator: Placebo
Placebo (IV)
Biological: Placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.
  • During the 28 day screening period, subjects must adequately complete the headache eDiary and must have headaches occurring on ≥ 15 to ≤ 26 days of which at least 8 must be migraine days.
  • Headache eDiary was completed on at least 24 of the 28 days prior to randomization.

Exclusion Criteria:

  • Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded.
  • Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections within 4 months prior to screening and during the screening period.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.
  • Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.
  • Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02974153

Contact: Alder Study Registration Call Center 866-580-5316

  Show 145 Study Locations
Sponsors and Collaborators
Alder Biopharmaceuticals, Inc.
Study Director: Timothy Whitaker, MD Alder Biopharmaceuticals, Inc.
  More Information

Responsible Party: Alder Biopharmaceuticals, Inc. Identifier: NCT02974153     History of Changes
Other Study ID Numbers: ALD403-CLIN-011
Study First Received: November 23, 2016
Last Updated: July 11, 2017

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on July 19, 2017